+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Infertility Drugs Market by Drug Class (Selective Estrogen Receptor Modulators, Gonadotropins, Dopamine Agonists), Distribution Channel, End User, and by Region - Global Forecast to 2022-2033

  • PDF Icon

    Report

  • 200 Pages
  • January 2023
  • Region: Global
  • Quintana Research and Consulting
  • ID: 5717243
The infertility drugs market size is estimated to be USD 3,707.5 million in 2022 and is expected to witness a CAGR of 6.67% during the forecast period 2023-2033. Higher incidence of infertility, existence of a potent drug pipeline, and expanding funding for infertility R&D are factors contributing to the market growth. Furthermore, various initiatives taken by government globally and rising adoption of a sedentary lifestyle by both men and women around the world are other factors supporting the market growth. However, high cost of patented products and strict regulatory framework for product approval is expected to hinder the growth.

Various initiatives taken by government globally is expected to propel the market growth during the projected period. Governments throughout the world have started a number of programmes to help individuals who are dealing with infertility by offering insurance coverage for therapy. For instance, the Ministry of Health, Labor, and Welfare (MHLW) announced the reimbursement under the national health insurance programme in March 2022. By reducing the cost by 70% and increasing the number of prescriptions for drugs, this programme improves patients' access to therapy.

Rising adoption of a sedentary lifestyle by both men and women around the world is predicted to fuel the market growth during the forecast period. For instance, the National Center for Drug Abuse Statistics reported in 2021 that during the COVID-19 lockdowns, about 60.0% of Americans increased their alcohol intake. Similar to this, the World Health Organization reported in 2021 that more than 300.0 million individuals in China, or over one-third of the world's population were smokers.

Segmentation

By Drug Class

The market is categorized into selective estrogen receptor modulators (SERMs), gonadotropins, dopamine agonists, aromatase inhibitors, and others. In 2022, the gonadotropins segment accounted for the highest revenue share due to the high price of the products and the rise in usage spurred by their greater efficacy. Some of the most popular gonadotropins used to treat people with infertility include Gonal-F, Follitism, Menopur, and Bravelle. Therefore, the high efficiency of gonadotropins may attract in a new target market and increase the source of revenue. Without health insurance, a chorionic gonadotropin injection typically costs approximately USD 397.83 per vial, whereas with insurance, the cost is USD 304.76 per vial. A phase 3 clinical research was also started in March 2022 by Bharat Serums and Vaccines Limited to assess the safety and effectiveness of recombinant human follicle-stimulating hormone (900 IU) in female patients between the ages of 20 and 39. Additionally, a phase 3 clinical trial for QL1012, a drug being developed by Qilu Pharmaceutical Co., Ltd. for ovarian stimulation, is presently underway.

By Distribution Channel

The market is categorized into online pharmacy, hospital pharmacy, and specialty & retail pharmacy. In the global market, the hospital pharmacy segment accounted for the largest revenue share in 2022 owing to rise in inpatient consultation visits and the requirement for doctor's prescriptions for drug purchase. As of February 2021, the United States reported receiving 72,786 inpatient visits from women seeking treatment consultation, according to a study by the NCBI. The online pharmacy market is anticipated to expand rapidly over the course of the forecast period. The presence of online clinical chains, which offer patients scheduled medication deliveries and promote patient discretion due to the social stigma connected with the problem, can be attributed with the segment's growth. Additionally, strategic alliances between leading fertility clinics and online platforms may help the online pharmaceutical market expand.

By End User

The market is segmented into women and men. In 2022, the women segment accounted for the largest revenue share owing to widespread accessibility of female infertility drugs. In the United States, 11% of women and 9% of men in reproductive age have infertility, according to the U.S. Department of Health and Human Services. In addition, the Fertility Society of Australia and New Zealand estimates that in Australia and New Zealand, about 40% of all women experience infertility problems. As a result, the market is driven by an increase in demand for infertility drugs due to the rising incidence of women's infertility. The women's segment is anticipated to increase at the fastest rate over the projection period due to the prevalence of diseases among women of reproductive age and the adoption of a sedentary lifestyle which includes drinking alcohol and smoking and dealing with ovulation. In 2020, it was determined that the prevalence of polycystic ovarian syndrome (PCOS) worldwide ranged from 2.2% to 48.0% in nations including the United States, China, India, and Australia, among others. Therefore, it is anticipated that increasing drug prescriptions and greater awareness of the disease in women will fuel the market.

Regional Markets

In 2022, North America region accounted for the highest revenue in the infertility drugs market and is expected to maintain its dominance during the forecast period. This is attributed to the introduction and fast adoption of numerous infertility drugs. It is anticipated that rising infertility research activity in the area can create additional job opportunities. For instance, Ferring B.V. and Igenomix signed a four-year research agreement in June 2020 to collaborate on the development of novel therapeutic products for the care of patients with problems associated with pregnancy. Asia Pacific is anticipated to increase at a significant rate over the forecast period. The existence of major market participants and their strategic efforts to create and promote novel infertility drugs to treat patients are attributed with the region's growth. For instance, the Ministry of Health, Labor, and Welfare (MHLW) approved 12 drugs for further infertility treatment indications in September 2022, including letrozole from Novartis AG and cabaser from Pfizer. It was predicted that this label expansion approval will increase the demand for innovative medications in Asia Pacific.

Competitor Insights

Some of the key players operating in the infertility drugs market are Abbott, Ferring B.V., Pfizer Inc., Merck & Co., Inc., Novartis AG, Mankind Pharma, Bayer AG, Teva Pharmaceutical Industries Ltd., Organon Group of Companies, and Sanofi.

To achieve a competitive edge, these companies are implementing a variety of growth strategies. Strategic partnerships, alliances, and agreements with different businesses and research institutions are seen to be the main strategies used by companies in this sector.

A generic version of Dydrogestrone tablets was created and released by Mankind Pharma in June 2022 for the treatment of patients' pregnancy-related problems in India. This launch was anticipated to increase demand for infertility treatments.

This comprehensive research report focuses on the global and regional market size and forecasts of diverse segments including drug class, distribution channel, and end user from 2023 to 2033.

Segmentation: Infertility Drugs Market Report 2022 - 2033

Drug Class (Revenue, USD Million), 2022 - 2033

  • Selective Estrogen Receptor Modulators (SERMs)
  • Gonadotropins
  • Dopamine Agonists
  • Aromatase Inhibitors
  • Others

Distribution Channel (Revenue, USD Million), 2022 - 2033

  • Online Pharmacy
  • Hospital Pharmacy
  • Specialty & Retail Pharmacy

End user (Revenue, USD Million), 2022 - 2033

  • Women
  • Men

By Region (Revenue, USD Million), 2022 - 2033

North America

  • U.S.
  • Canada

Europe

  • Germany
  • France
  • UK
  • Spain
  • Italy
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of APAC

Latin America

  • Brazil
  • Mexico
  • Argentina
  • Rest of LATAM

Middle East & Africa

  • South Africa
  • GCC
  • Rest of MEA

Table of Contents

1. Research Methodology
1.1. Study Objectives
1.2. Study Scope
1.3. Research Framework
1.3.1. Research Models
1.3.1.1. Bottom-up Approach
1.3.1.2. Top-down Approach
1.3.1.3. Data Triangulation
1.3.2. Data Analysis
1.3.2.1. Data Validation
1.3.2.2. Market Size Estimation
1.3.2.3. Market Forecast Model

2. Introduction: Infertility Drugs

3. Executive Summary

4. Market Dynamics
4.1. Market Drivers
4.1.1. Driver 1
4.1.2. Driver 2
4.1.3. Driver 3
4.1.4. Driver 4
4.2. Market Restraint
4.2.1. Restraint 1
4.2.2. Restraint 2
4.2.3. Restraint 3
4.3. Market Opportunities
4.3.1. Opportunity 1
4.3.2. Opportunity 2
4.3.3. Opportunity 3
4.4. Market Trends
4.4.1. Trend 1
4.4.2. Trend 2
4.4.3. Trend 3
4.5. Market Challenges
4.5.1. Challenge 1
4.5.2. Challenge 2
4.5.3. Challenge 3

5. Market Environment Analysis
5.1. Porter’s 5 Forces Analysis
5.2. PESTEL Analysis
5.3. SWOT Analysis

6. COVID-19 Impact Analysis: Infertility Drugs Market

7. Market Analysis by Drug Class
7.1. Selective Estrogen Receptor Modulators (SERMs)
7.1.1. Selective Estrogen Receptor Modulators (SERMs)
7.2. Gonadotropins
7.2.1. Gonadotropins Market Forecast, 2022-2033 (USD Million)
7.3. Dopamine Agonists
7.3.1. Dopamine Agonists Market Forecast, 2022-2033 (USD Million)
7.4. Aromatase Inhibitors
7.4.1. Aromatase Inhibitors Market Forecast, 2022-2033 (USD Million)
7.5. Others
7.5.1. Others Market Forecast, 2022-2033 (USD Million)

8. Market Analysis by Distribution Channel
8.1. Online Pharmacy
8.1.1. Online Pharmacy Market Forecast, 2022-2033 (USD Million)
8.2. Hospital Pharmacy
8.2.1. Hospital Pharmacy Market Forecast, 2022-2033 (USD Million)
8.3. Specialty & Retail Pharmacy
8.3.1. Specialty & Retail Pharmacy Market Forecast, 2022-2033 (USD Million)

9. Market Analysis by End User
9.1. Women
9.1.1. Women Market Forecast, 2022-2033 (USD Million)
9.2. Men
9.2.1. Men Market Forecast, 2022-2033 (USD Million)

8. Regional Market Analysis
8.1. Regional Market Trends Analysis

9. North America Infertility Drugs Market
9.1. North America Infertility Drugs Market
9.1.1. North America Market Size and Forecast, 2022-2033 (USD Million)
9.1.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
9.1.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
9.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
9.2. U.S. Infertility Drugs Market
9.2.1. U.S. Market Size and Forecast, 2022-2033 (USD Million)
9.2.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
9.2.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
9.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
9.3. Canada Infertility Drugs Market
9.3.1. Canada Market Size and Forecast, 2022-2033 (USD Million)
9.3.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
9.3.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
9.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

10. Europe Infertility Drugs Market
10.1. Europe Infertility Drugs Market
10.1.1. Europe Market Size and Forecast, 2022-2033 (USD Million)
10.1.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.1.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
10.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.2. Germany Infertility Drugs Market
10.2.1. Germany Market Size and Forecast, 2022-2033 (USD Million)
10.2.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.2.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
10.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.3. UK Infertility Drugs Market
10.3.1. UK Market Size and Forecast, 2022-2033 (USD Million)
10.3.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.3.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
10.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.4. France Infertility Drugs Market
10.4.1. France Market Size and Forecast, 2022-2033 (USD Million)
10.4.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.4.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
10.4.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.5. Spain Infertility Drugs Market
10.5.1. Spain Market Size and Forecast, 2022-2033 (USD Million)
10.5.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.5.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
10.5.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.6. Italy Infertility Drugs Market
10.6.1. Italy Market Size and Forecast, 2022-2033 (USD Million)
10.6.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.6.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
10.6.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
10.7. Rest of Europe Infertility Drugs Market
10.7.1. Rest of Europe Market Size and Forecast, 2022-2033 (USD Million)
10.7.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
10.7.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
10.7.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

11. Asia Pacific Infertility Drugs Market
11.1. Asia Pacific Infertility Drugs Market
11.1.1. Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
11.1.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.1.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.2. Japan Infertility Drugs Market
11.2.1. Japan Market Size and Forecast, 2022-2033 (USD Million)
11.2.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.2.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.3. China Infertility Drugs Market
11.3.1. China Market Size and Forecast, 2022-2033 (USD Million)
11.3.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.3.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.4. India Infertility Drugs Market
11.4.1. India Market Size and Forecast, 2022-2033 (USD Million)
11.4.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.4.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.4.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.5. South Korea Infertility Drugs Market
11.5.1. South Korea Market Size and Forecast, 2022-2033 (USD Million)
11.5.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.5.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.5.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.6. Australia Infertility Drugs Market
11.6.1. Australia Market Size and Forecast, 2022-2033 (USD Million)
11.6.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.6.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.6.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
11.7. Rest of Asia Pacific Infertility Drugs Market
11.7.1. Rest of Asia Pacific Market Size and Forecast, 2022-2033 (USD Million)
11.7.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
11.7.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
11.7.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

12. Latin America Infertility Drugs Market
12.1. Latin America Infertility Drugs Market
12.1.1. Latin America Market Size and Forecast, 2022-2033 (USD Million)
12.1.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.1.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.2. Brazil Infertility Drugs Market
12.2.1. Brazil Market Size and Forecast, 2022-2033 (USD Million)
12.2.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.2.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.3. Mexico Infertility Drugs Market
12.3.1. Mexico Market Size and Forecast, 2022-2033 (USD Million)
12.3.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.3.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.4. Argentina Infertility Drugs Market
12.4.1. Argentina Market Size and Forecast, 2022-2033 (USD Million)
12.4.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.4.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.4.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
12.5. Rest of Latin America Infertility Drugs Market
12.5.1. Rest of Latin America Market Size and Forecast, 2022-2033 (USD Million)
12.5.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
12.5.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
12.5.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

13. MEA Infertility Drugs Market
13.1. MEA Infertility Drugs Market
13.1.1. MEA Market Size and Forecast, 2022-2033 (USD Million)
13.1.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
13.1.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
13.1.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.2. GCC Infertility Drugs Market
13.2.1. GCC Market Size and Forecast, 2022-2033 (USD Million)
13.2.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
13.2.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
13.2.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.3. South Africa Infertility Drugs Market
13.3.1. South Africa Market Size and Forecast, 2022-2033 (USD Million)
13.3.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
13.3.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
13.3.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)
13.4. Rest of MEA Infertility Drugs Market
13.4.1. Rest of MEA Market Size and Forecast, 2022-2033 (USD Million)
13.4.1.1. Market Size and Forecast by Drug Class, 2022-2033 (USD Million)
13.4.1.2. Market Size and Forecast by Distribution Channel, 2022-2033 (USD Million)
13.4.1.3. Market Size and Forecast by End User, 2022-2033 (USD Million)

14. Competitor Analysis
14.1. Market Share Analysis, 2022
14.2. Major Recent Developments, 2019-2022

15. Company Profiles
15.1. Abbott
15.1.1. Company Snapshot
15.1.2. Company Overview
15.1.3. Financial Analysis
15.1.4. Product Benchmarking
15.1.5. Recent Developments
15.2. Ferring B. V.
15.2.1. Company Snapshot
15.2.2. Company Overview
15.2.3. Financial Analysis
15.2.4. Product Benchmarking
15.2.5. Recent Developments
15.3. Pfizer Inc.
15.3.1. Company Snapshot
15.3.2. Company Overview
15.3.3. Financial Analysis
15.3.4. Product Benchmarking
15.3.5. Recent Developments
15.4. Merck & Co., Inc.
15.4.1. Company Snapshot
15.4.2. Company Overview
15.4.3. Financial Analysis
15.4.4. Product Benchmarking
15.4.5. Recent Developments
15.5. Novartis AG
15.5.1. Company Snapshot
15.5.2. Company Overview
15.5.3. Financial Analysis
15.5.4. Product Benchmarking
15.5.5. Recent Developments
15.6. Mankind Pharma
15.6.1. Company Snapshot
15.6.2. Company Overview
15.6.3. Financial Analysis
15.6.4. Product Benchmarking
15.6.5. Recent Developments
15.7. Bayer AG
15.7.1. Company Snapshot
15.7.2. Company Overview
15.7.3. Financial Analysis
15.7.4. Product Benchmarking
15.7.5. Recent Developments
15.8. Teva Pharmaceutical Industries Ltd.
15.8.1. Company Snapshot
15.8.2. Company Overview
15.8.3. Financial Analysis
15.8.4. Product Benchmarking
15.8.5. Recent Developments
15.9. Organon Group of Companies
15.9.1. Company Snapshot
15.9.2. Company Overview
15.9.3. Financial Analysis
15.9.4. Product Benchmarking
15.9.5. Recent Developments
15.10. Sanofi
15.10.1. Company Snapshot
15.10.2. Company Overview
15.10.3. Financial Analysis
15.10.4. Product Benchmarking
15.10.5. Recent Developments
15.11. Company 11
15.11.1. Company Snapshot
15.11.2. Company Overview
15.11.3. Financial Analysis
15.11.4. Product Benchmarking
15.11.5. Recent Developments
15.12. Company 12
15.12.1. Company Snapshot
15.12.2. Company Overview
15.12.3. Financial Analysis
15.12.4. Product Benchmarking
15.12.5. Recent Developments
15.13. Company 13
15.13.1. Company Snapshot
15.13.2. Company Overview
15.13.3. Financial Analysis
15.13.4. Product Benchmarking
15.13.5. Recent Developments
15.14. Company 14
15.14.1. Company Snapshot
15.14.2. Company Overview
15.14.3. Financial Analysis
15.14.4. Product Benchmarking
15.14.5. Recent Developments
15.15. Company 15
15.15.1. Company Snapshot
15.15.2. Company Overview
15.15.3. Financial Analysis
15.15.4. Product Benchmarking
15.15.5. Recent Developments

16. Conclusion

17. Recommendations

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Abbott
  • Ferring B.V.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Mankind Pharma
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Organon Group of Companies
  • Sanofi.